DEOM

Deom Biopharma is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on developing innovative small molecule therapies for autoimmune and inflammatory diseases. The company specializes in the discovery of highly selective kinase inhibitors designed to provide superior safety and efficacy compared to first-generation treatments. Its lead program, DM-001, is a highly selective Tyrosine Kinase 2 (TYK2) inhibitor currently in Phase 2 clinical development for indications including plaque psoriasis and atopic dermatitis. Deom's pipeline also features DM-002, a selective Janus Kinase 1 (JAK1) inhibitor, alongside several early-stage programs. Supported by prominent investors like 6 Dimensions Capital and Boyu Capital, Deom aims to deliver next-generation oral therapies to patients worldwide.